ChronoScale Holdings Corporation (LON:0IFR)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.83B +48,292.7% |
| Revenue (ttm) | 62.61M |
| Net Income | -53.97M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953 |
| Open | 25.52 |
| Previous Close | 24.27 |
| Day's Range | 22.62 - 26.21 |
| 52-Week Range | 8.71 - 29.60 |
| Beta | 1.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 27, 2026 |
About ChronoScale Holdings
ChronoScale Holdings Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and long-term operational execution. The company was formerly known as ChronoScale Corporation and changed its name to ChronoScale Holdings Corporation in July 2026. The company was incorporated in 2026 and is based in Dallas, Texas. ChronoScale Holdings Corporation operates as a subsidiary of... [Read more]
News
ChronoScale falls -19.5%
ChronoScale (CHRN) is down -19.5%, or -$5.78 to $23.85.
ChronoScale falls -18.5%
ChronoScale (CHRN) is down -18.5%, or -$5.48 to $24.15.
ChronoScale Holdings Registration statement: Registration filing
ChronoScale Holdings filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
ChronoScale falls -17.9%
ChronoScale (CHRN) is down -17.9%, or -$3.97 to $18.25.
ChronoScale files to sell 1.1M shares of common stock for holders
17:26 EDT ChronoScale (CHRN) files to sell 1.1M shares of common stock for holders
ChronoScale Holdings Registration statement: Registration filing
ChronoScale Holdings filed a registration statement on June 30, 2026, providing details about a securities offering with the SEC.
ChronoScale Stock (CHRN) Surges on Rising Investor Interest In AI
ChronoScale stock was up on Thursday as investors take interest in AI-related companies.
ChronoScale appoints Raj Jegannathan as CTO, Lawrence Lam as CPO
ChronoScale (CHRN) announced the appointments of Raj Jegannathan as chief technology officer, or CTO, and Lawrence Lam as chief product officer, or CPO. Jegannathan joins ChronoScale as CTO after an…
ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy
DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelli...
ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ: CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced t...
Ekso Bionics Prices $5.852 million Private Placement
SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale
DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artific...
Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch's Groundbreaking BalanceTutor™ Rehabilitation System
SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for ...
Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced th...
Ekso Bionics Reports Third Quarter 2025 Financial Results
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics Reports Second Quarter 2025 Financial Results
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today ann...
Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industr...
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company an...
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced tha...